scholarly journals The role of external radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer: a matched pair analysis

2001 ◽  
Vol 51 (3) ◽  
pp. 198-199
Author(s):  
L. Potters ◽  
P. Fearn ◽  
M. Kattan
Keyword(s):  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Matched Pair ◽  
Prostate Brachytherapy ◽  
External Radiotherapy ◽  
Matched Pair Analysis ◽  
Pair Analysis

Examining the Role of Neoadjuvant Androgen Deprivation in Patients Undergoing Prostate Brachytherapy

2000 ◽  
Vol 18 (6) ◽  
pp. 1187-1192 ◽  
Author(s):  
Louis Potters ◽  
Taryn Torre ◽  
Richard Ashley ◽  
Steven Leibel
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Matched Pair ◽  
Prostate Brachytherapy ◽  
Absolute Increase ◽  
Androgen Ablation ◽  
Matched Pair Analysis ◽  
Pair Analysis

PURPOSE: To assess the role of neoadjuvant androgen deprivation (NAAD) and transperineal interstitial permanent prostate brachytherapy (TIPPB) using a matched-pair analysis selected from a large cohort of patients undergoing TIPPB. PATIENTS AND METHODS: Six hundred twelve consecutive patients with clinically confined prostate cancer were treated between June 1992, and January 1997, with permanent ultrasound-guided TIPPB with either palladium-103 or iodine-125 as monotherapy or combined with external radiation. Patients with prostate glands ≥ 60 g underwent treatment with NAAD before TIPPB to reduce the prostate volume (n = 163). The median duration of NAAD was 3.4 months before TIPPB (range, 1 to 8 months). To assess the benefit of NAAD, a matched-pair analysis was performed. The American Society of Therapeutic Radiology and Oncology Consensus Group definition of prostate-specific antigen (PSA) relapse-free survival (RFS) was used with the added caveat of an absolute increase of ≥ 1.0 ng/mL. Differences in pretreatment PSA, Gleason scores, and stage were analyzed by Kaplan-Meier curves and the log-rank test. RESULTS: Two hundred sixty-three patients were matched, with a median follow-up duration of 46 months (range, 24 to 76 months). The actuarial 5-year PSA-RFS rate for all 263 patients is 86.5%. The 5-year PSA-RFS rate for patients treated with NAAD and TIPPB was 87.1% compared with 86.9% for those treated with TIPPB only (P = .935). Subgroup analysis by Gleason score groupings, pretreatment PSA, or stage of disease failed to identify any factors for which androgen ablation was beneficial. CONCLUSION: We were unable to identify any improvement with the addition of NAAD to TIPPB in patients with localized prostate cancer in this retrospective matched-pair analysis. Furthermore, there was no subset for which the addition of NAAD was found to be beneficial. Clarification of the role and duration of NAAD in patients with early-stage prostate cancer will require prospective data.

Localized prostate cancer and salvage treatment: EBRT first + salvage HIFU or HIFU first + salvage EBRT? A single-institution matched pair analysis over a 20-year period.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 77-77
Author(s):  
Gilles Pasticier ◽  
Ji-Wann Lee ◽  
Sebastien Crouzet ◽  
J Soria ◽  
Christelle Medollima ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Rate ◽  
Side Effects ◽  
Localized Prostate Cancer ◽  
External Beam Radiation ◽  
Matched Pair ◽  
Single Institution ◽  
Matched Pair Analysis ◽  
Salvage Hifu ◽  
Pair Analysis

77 Background: In the field of curative treatment for localized prostate cancer, HIFU (High Intensity Focused ultrasound) is one of salvage option after EBRT(external beam radiation therapy) failure and EBRT is the standard salvage option for local relapse after HIFU.Our aim was to compare and evaluate the oncologic outcomes between HIFU first + salvage EBRT versus EBRT first +salvage HIFU. Methods: Using a matched pair analysis, 342 Patients (171 in each group) treated between 1994 and 2014 in the same institution were prospectively followed and matched to a 1:1 basis. Outcome measurements: Overall Survival Rate(OSR), cancer specific(CSSR) and metastasis free (MFSR) survival rates were the primary endpoints. Secondary endpoints were survival rate free of hormone therapy (HTFR) and the rate of side effects Clavien score ≥ 3. Results: Mean follow-up were 114 and 124 months for HIFU+ S-EBRT and EBRT + S-HIFU respectively. At 7 years from the primary treatment , the MFSR were significantly better after HIFU first +S- EBRT than after EBRT first+S- HIFU: 96% vs 91%% (p:0.011). The OSR and the CSSR were not significantly different in the two arms (97% and 99% after HIFU+S- EBRT versus 96% and 98% after EBRT+S- HIFU). The HTFR at 7 years was significantly different (p <0.001) after HIFU+ S-EBRT than after EBRT+ S-HIFU 90% versus 69%. In multivariable Cox regression, the initial Gleason sum ≥ 8 and the treatment strategy were predictors of MFSR (risk ratio 3.2 for treatment modality). The rate of side effect Clavien score≥ 3 was significantly higher (p:0.01) in the EBRT+ S-HIFU arm than in the HIFU+ S-EBRT arm. The rate of urinary toxicity (severe incontinence and bladder outlet obstruction) were worse in the EBRT+ S-HIFU arm than in HIFU+S-EBRT arm: 9.4% and 15.2% vs 1.2% and 7.6% (p:0.01 and 0.078). Conclusions: In this single-institution Matched Pair comparison, the MFSR and HTFR were significantly better in the HIFU+S-EBRT arm than in the EBRT+S-HIFU arm. The rate of urinairy toxicity and Clavien≥3 side-effects were Higher in the EBRT + S-HIFU arm than in the HIFU + S-EBRT arm.

HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis

2018 ◽  
Vol 36 (12) ◽  
pp. 2035-2041 ◽  
Author(s):  
Bernd Rosenhammer ◽  
Eva M. Lausenmeyer ◽  
Roman Mayr ◽  
Maximilian Burger ◽  
Christian Eichelberg
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Detection Rate ◽  
Cancer Detection Rate ◽  
Matched Pair ◽  
Prostate Cancer Detection ◽  
Matched Pair Analysis ◽  
Pair Analysis
Sign in / Sign up

Export Citation Format

Share Document